文献速递血栓与止血

Ad26.COV2.S相关疫苗诱导免疫性血栓性血小板减少症(VITT)的持续性及VITT抗体的特异性检测

Persistence of Ad26.COV2.S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies.
PubMed 文献 · Am J Hematol · 2022-02-21

本研究探讨Ad26.COV2.S疫苗接种后VITT抗体的持续性与检测方法,发现患者PF4-聚阴离子ELISA强阳性但SRA常阴性,PF4依赖的P-选择素表达试验(PEA)可一致诊断;多数抗体在PF4-聚阴离子ELISA中持续>5个月,PEA更早转阴;新型未复合PF4 ELISA可特异性区分VITT与自发HIT、HIT及疑似HIT患者。

要点

  • Ad26.COV2.S相关VITT患者PF4-聚阴离子ELISA均强阳性,但SRA常阴性。
  • PEA使用PF4处理血小板而非肝素,可一致诊断Ad26.COV2.S相关VITT。
  • 多数VITT抗体在PF4-聚阴离子ELISA中持续>5个月,PEA更早转阴。

核心结论

  • Ad26.COV2.S相关VITT抗体具有持续性,未复合PF4 ELISA对VITT诊断似乎兼具敏感性和特异性。

研究设计与样本

  • 本研究为实验室检测方法研究,纳入Ad26.COV2.S相关VITT患者及HIT、自发HIT、疑似HIT等对照人群,评估PF4-聚阴离子ELISA、SRA、PEA及新型未复合PF4 ELISA的表现。

主要发现

  • Ad26.COV2.S相关VITT患者在PF4-聚阴离子ELISA中均强阳性,但SRA常阴性。
  • PF4依赖的P-选择素表达试验(PEA)使用PF4处理的血小板而非肝素,可一致诊断Ad26.COV2.S相关VITT。
  • 多数Ad26.COV2.S相关VITT抗体在PF4-聚阴离子ELISA中持续>5个月,而PEA更早转阴。
  • 两名患者在急性表现后6个月出现原因不明的轻度持续性血小板减少(140-150 x 10^3/µL)。
  • 新型未复合PF4 ELISA可特异性区分Ad26.COV2.S和ChAdOx1 nCoV-19相关VITT与自发HIT、HIT及常见HIT疑似患者(后者PF4/聚阴离子ELISA阳性但功能试验阴性)。

关键数值与推荐

  • Ad26.COV2.S相关VITT患者PF4-聚阴离子ELISA均强阳性,SRA常阴性。
  • PEA可一致诊断Ad26.COV2.S相关VITT。
  • 多数VITT抗体在PF4-聚阴离子ELISA中持续>5个月。
  • 两名患者急性表现后6个月血小板计数为140-150 x 10^3/µL。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rare cases of COVID-19 vaccinated individuals develop anti-platelet factor 4 (PF4) antibodies that cause thrombocytopenia and thrombotic complications, a syndrome referred to as vaccine-induced immune thrombotic thrombocytopenia (VITT). Currently, information on the characteristics and persistence of anti-PF4 antibodies that cause VITT after Ad26.COV2.S vaccination is limited, and available diagnostic assays fail to differentiate Ad26.COV2.S and ChAdOx1 nCoV-19-associated VITT from similar clinical disorders, namely heparin-induced thrombocytopenia (HIT) and spontaneous HIT. Here we demonstrate that while Ad26.COV2.S-associated VITT patients are uniformly strongly positive in PF4-polyanion enzyme-linked immunosorbent assays (ELISAs); they are frequently negative in the serotonin release assay (SRA). The PF4-dependent p-selectin expression assay (PEA) that uses platelets treated with PF4 rather than heparin consistently diagnosed Ad26.COV2.S-associated VITT. Most Ad26.COV2.S-associated VITT antibodies persisted for >5 months in PF4-polyanion ELISAs, while the PEA became negative earlier. Two patients had otherwise unexplained mild persistent thrombocytopenia (140-150 x 103 /µL) 6 months after acute presentation. From an epidemiological perspective, differentiating VITT from spontaneous HIT, another entity that develops in the absence of proximate heparin exposure, and HIT is important, but currently available PF4-polyanion ELISAs and functional assay are non-specific and detect all three conditions. Here, we report that a novel un-complexed PF4 ELISA specifically differentiates VITT, secondary to both Ad26.COV2.S and ChAdOx1 nCoV-19, from both spontaneous HIT, HIT and commonly-encountered HIT-suspected patients who are PF4/polyanion ELISA-positive but negative in functional assays. In summary, Ad26.COV2.S-associated VITT antibodies are persistent, and the un-complexed PF4 ELISA appears to be both sensitive and specific for VITT diagnosis.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Kanack AJ, Singh B, George G, et al. Persistence of Ad26.COV2.S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies. Am J Hematol. 2022. PMID: 35132672. doi:10.1002/ajh.26488

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。